Uremia is associated with bleeding diathesis. Platelet adhesion to the subendothelium is inhibited by a factor in uremic plasma that may play a role in the disturbed hemostasis of uremic patients. In the formation of the hemostatic plug, platelet adherence is followed by stimulus-induced platelet aggregation and reinforcement by thrombin-generated fibrin. To study these processes in uremic blood, a newly developed thrombosis model was used. Perfusates anticoagulated with low-molecular-weight heparin were circulated over a matrix of stimulated cultured endothelial cells. By stimulation of the endothelial cells, tissue factor was synthesized and deposited in the matrix. When this tissue factor rich-matrix was exposed to flowing blood, local thrombin was formed via activation of the extrinsic coagulation pathway. With this system, platelet adhesion, thrombin-dependent platelet activation, and fibrin formation can all be studied at the same surface. In addition to an adhesion defect, decreased aggregate formation was also found in uremic perfusates. Normal platelets in uremic plasma showed similar results, which indicates that a factor in uremic plasma caused this adhesion and aggregation defect. Platelet aggregation in the system was dependent on endogeneously formed thrombin. Fibrinopeptide A generation, however, was normal in uremic perfusates; therefore, uremic plasma has a normal capacity to form thrombin. Resuspension of washed uremic platelets in control plasma did not reverse the aggregation defect in perfusions. In contrast, aggregometer studies with isolated uremic platelets could not detect an abnormal response to threshold concentrations of exogenous thrombin. Thus, uremic toxin (s) cause defective aggregate formation in flow, but not necessarily in the aggregometer. This apparent discrepancy may be due to the higher shear forces in the flow system, which may prevent aggregate formation that is allowed in the aggregometer. Another explanation, that uremic platelets are less responsive to locally formed thrombin than they are to exogenously added thrombin, seems less likely. [Arteriosclerosis and Thrombosis 1991;ll:733-744)
T he association between uremia and bleeding was first published by Riesman in 1907 1 and has been repeatedly confirmed since. Regular dialysis treatment, the avoidance of drugs that impair platelet function, and the prevention of vitamin K-dependent coagulation factor deficiencies have eradicated the major hemorrhage that was commonly seen in the time before dialysis treatment. 2 Nowadays, clinical manifestations of bleeding 734
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simulated by perfusion experiments. It has been established that platelet count, 12 hematocrit, 12 and blood flow 13 -16 determine the amount of platelets available for adhesion. The low hematocrit in uremia was thus established as a major 17 - 19 but not the only 17 - 20 cause of uremic bleeding. Additionally, platelet adhesion to the subendothelium is inhibited by a factor in uremic plasma. 21 However, in the formation of the hemostatic plug, platelet adherence is followed by stimulus-induced platelet aggregation and reinforcement by thrombingenerated fibrin. 11 In this article, we investigated the entirety of thrombus formation in uremic blood under well-defined flow conditions. We made use of a recently developed thrombosis model. 22 Blood was anticoagulated with low-molecular-weight heparin (LMWH) and was circulated through a specially constructed perfusion chamber 23 over a matrix of stimulated cultured endothelial cells. 22 The stimulation of endothelial cells results in increased synthesis and deposition of tissue factor in the matrix. The tissue factor-rich matrix leads, when exposed to blood, to local thrombin formation via activation of the extrinsic coagulation pathway; platelet adhesion, thrombin-dependent platelet activation, and fibrin deposition can thus be studied at the same surface. With this model, an aggregation defect as well as an adhesion defect was found with uremic blood. The observed defects were caused by a plasma factor, as was determined in perfusion experiments with reconstituted perfusates.
Methods

Patients
Ten patients with clinically stable chronic renal failure, four women and six men aged 57±10 years (mean±SD; range, 46-71 years) who received maintenance hemodialysis treatment two or three times a week for more than 6 months were enrolled in the study. Patients gave informed consent for the blood collection necessary for the described experiments. The patients either were not hypertensive or had hypertension that was medically controlled. Patients refrained from taking any medication that might possibly affect platelet function or coagulation tests unless stated otherwise. No androgens or immunosuppressive drugs were used; the participating women were not pregnant. There was no hematologic evidence of aluminum intoxication (acquired microcytosis without iron deficiency). Patients had no diabetes mellitus and no hepatitis. Patients did not receive blood transfusions in the 2 weeks before the experiments. Their mean±SD predialysis serum urea level was 29.1±5.1 mmol/1 (patient range, 22.6-36.2 mmol/1; normal range, 3.0-7.5 mmol/1); the creatinine level was 1,256±137 junol/1 (patient range, 1,005-1,415 jtmol/1; normal range, 50-120 jtmol/1).
Studies of Patients
Samples for a set of laboratory tests were drawn from patients just before the start of one of their regular hemodialysis treatments. Five milliliters of whole blood, anticoagulated with 2 mM EDTA, was collected for determination of hematocrit, mean cell volume, and platelet count (model-S Coulter counter, Harpenden, U.K.).
The bleeding time of all patients was determined by one single experienced technician using a Simplate-II device (General Diagnostics, Morris Plains, N.J.) with a venous pressure of 40 mm Hg and with a horizontal incision on the volar surface of the forearm, 10 or with the use of a disposable 2.5-mm lancet (Microlance, Becton-Dickinson & Co., Rutherford, N.J.) with which three punctures were made on the volar surface of the forearm again at a venous pressure of 40 mm Hg as originally described by Ivy et al. 24 Fibrinogen, coagulation factors, antithrombin III, and von Willebrand (vWF) factor-related properties were determined in blood collected into 1/10 volume 130 mM trisodium citrate. Reference plasma was a freshly frozen plasma pool from 40 normal subjects stored at -70°C. Plasma fibrinogen level was determined according to Clauss. 25 Prothrombin times and activated partial thromboplastin times (APTT) were performed by standard methods using thromboplastin-C (Dade, Diagnostics Inc., Aquada, Puerto Rico) and APTT reagent (Boehringer Mannheim GmbH, Mannheim, F.R.G.), respectively. Factor VIII, II, V, VII, and X coagulant activity was measured in a one-stage clotting assay 26 -27 with commercially available deficient plasmas (George King Bio-Medical Inc., Overland Park, Kan.) as the substrate. Antithrombin III was assayed with an antithrombin III kit (KabiVitrum, Stockholm, Sweden) according to the manufacturer's instructions. vWF-related antigen (vWF: Ag) was determined by an elecrroimmunodifrusion assay with rabbit anti-vWF serum raised against human vWF 28 ; the ristocetin cofactor activity was measured with formalin-fixed platelets and 1 mg/ml ristocetin sulfate 29 (H. Lundbeck & Co., Copenhagen, Denmark). Platelet aggregation studies were performed at 37°C in a Payton Dual-Channel Aggregation Module (Payton Associates, Scarborough, Canada) or a PAP-4 aggregometer (Bio/Data, Hatboro, Pa.) with ADP (Dade; 25 fjM final concentration) added to plateletrich plasma (PRP) adjusted to 250,000 platelets/Ail by dilution with autologous platelet-poor plasma (PPP). Thromboxane B2 production during the aggregation response to exogenous arachidonate (Bio/Data; 1.5 mM, 1 and 10 minutes after addition) or exogenous equine collagen (Hormon Chemie, Munich, F.R.G.; 4 /xg/ml) was determined by radioimmunoassay (DuPont Biomedical Products, Boston, Mass.). Total platelet ATP and ADP were measured with the firefly luciferase technique described by Holmsen et al. 30 Serotonin in platelets was assayed according to Rao et al. 31 Levels of ^-thromboglobulin and platelet factor 4 (PF4) in plasma were determined with radioimmunoassays (from Amersham International, Amersham, U.K., and Abbot Laboratories, North Chicago, 111., respectively).
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were isolated from umbilical cords according to the method originally described by Jaffe et al 32 with some minor modifications. 33 Cells were identified by their typical cobblestonelike pattern and endothelial characteristics such as the presence of vWF.
32
- 34 For the experiments described here, HUVECs of the second passage were subcultured on gelatin-coated Thermanox coverslips (Lab-Tek Division, Miles Laboratories, Naperville, 111.). Before seeding the cells, gelatin was fixated with 0.5% glutardialdehyde. 35 Cell monolayers grown to confluence in 5-7 days were used (50,000 cells/cm 2 ). At confluence, the cells were stimulated for 18 hours by addition of 20 ng/ml 4£-phorbol-12-myristate-13-acetate (Sigma Chemical Co., St. Louis, Mo.). PMA was dissolved in dimethylsulfoxide and subsequently diluted 1:1,000, vol/vol, in the culture medium. Addition of dimethylsulfoxide alone at the same concentration had no influence on the cells. To isolate the extracellular matrix (ECM), the endothelium was removed by exposure to 0.1 M NH4OH at room temperature for 30 minutes and gentle shaking. 36 The isolated matrixes were washed three times with phosphatebuffered saline (1:10, vol/vol, 0.1 M NaH 2 PO 4 buffer, pH 7.4, in 150 mM NaCl; PBS) and used the same day for perfusion studies.
Perfusate Blood Collection and Anticoagulation
LMWH (Fragmin, kindly provided by KabiVitrum) with a mean molecular weight of 4,500 and an anti-Xa/ antithrombin ratio of 4 (165 units/mg anti-factor Xa, 40 units/mg antithrombin activity as measured by kaolincephalin clotting time) was diluted in saline (200 anti-Xa units/ml). Blood of patients was collected by clean venipuncture in 1:10, vol/vol, of this heparin-saline just before one of their regular hemodialysis treatments. Healthy human donors served as controls. Hematocrit and total blood volume were measured, and the plasma volume was calculated. The LMWH concentration in plasma was subsequently adjusted to 33 units/ml in both patient and control plasmas. Experiments (not shown) in which equal amounts of LMWH were added to patient or to control plasma (both anticoagulated with 20 mM trisodium citrate) showed comparable anti-Xa activity in both plasmas. At equal concentrations, LMWH caused a somewhat lower (10-30%) antithrombin activity (measured by kaolin-cephalin clotting time) in patient plasma than was found in control plasma. As described before, 22 this LMWH concentration was sufficient to inhibit activation of coagulation during collection, manipulation, and perfusion of the blood through a perfusion chamber with a matrix of nonstimulated endothelial cells. LMWH did not have effects on the number of platelets in the perfusates.
Perfusates
All perfusates were adjusted to similar hematocrits and platelet counts; they were all used in a final volume of 15 ml and were kept at room temperature before use.
Standardization of perfusates. Standardization of perfusates was obtained by lowering the hematocrit of whole blood of controls by addition of autologous PPP and by increasing the hematocrit of whole blood of patients by addition of autologous red blood cells (RBCs). In this way, similar hematocrits and platelet counts (30%, and 150,000 platelets/^,1, respectively) were obtained for both patients and controls.
In experiments to investigate the contribution of only patient plasma or only patient platelets to the perfusion results, we reconstituted perfusates from PPP, washed platelets, and washed RBCs. By this procedure, three types of perfusate were obtained: 1) control platelets resuspended in patient plasma with control RBCs; 2) patient platelets resuspended in control plasma with control RBCs; and 3) as reference perfusate, control platelets resuspended in control plasma with control RBCs. PPP was obtained by centrifugation of patient or control whole blood (10 minutes at 3,000g, 22°C), and before addition of platelets, pH was adjusted to 7.4 with 1.0N HC1. Washed platelets of controls and patients were prepared from control and patient PRP by methods previously described. 37 Platelet concentrations in the reconstituted perfusates were all adjusted to 190,000 platelets/pl A Model 810 Platelet Analyzer (Baker Instruments, Allentown, Pa.) was used for counting the platelets. Washed RBCs were obtained from healthy donors with type O, rhesus-positive blood; after centrifugation of whole blood, PRP and PPP were collected, and the remaining RBCs were washed three times by sequential resuspension in saline containing 5 mM a-D-glucose followed by centrifugation (5 minutes at 3,000g, 22°C). Before use in reconstituted perfusates, RBCs were "packed" by centrifugation (10 minutes at 4,000g, 22°C). Washed RBCs were added to the reconstituted PRP just before the start of the perfusions. In the reconstituted perfusates, the hematocrit was adjusted to 40%.
Perfusion Chambers and Surfaces
Perfusions with steady flow 12 were performed in a rectangular perfusion chamber, which has been described and characterized extensively elsewhere. 23 This perfusion chamber contains two circular knobs. On each knob two Thermanox (2x1.62-cm 2 ) coverslips (Lab-Tek) can be mounted. Cultured cells or their ECMs present on these coverslips were in this way exposed to the flowing blood in the chamber.
Perfusions
The coverslips in the rectangular chamber were rinsed before the start of the perfusions with 25 ml prewarmed (37°C) 10 mM A r -2-hydroxyethylpiperazine-/V'-2-ethanesulfonic acid (HEPES)-buffered saline, pH 7.4. Perfusates prewarmed for 5 minutes at 37°C were then circulated for 5 minutes at a wall shear rate of 1300 sec- 1 . 22 The coverslips with matrix were removed from the rectangular chamber, and the system was thoroughly rinsed with 30 ml HEPESsaline after each perfusion run. The perfused coverslips were rinsed with 5 ml HEPES-saline and fixed with 0.5% glutardialdehyde in PBS as previously described. 37 Coverslips with matrix were subsequently postfixed with 2.0% OsO 4 , dehydrated, and embedded in Epon as earlier published. 13 The Epon with the embedded matrix and the adhering platelets were separated from the coverslip by thermoshock. 22 
Evaluation
One-micron-thick sections of the Epon-embedded matrix were prepared and stained with Methylene Blue and Basic Fuchsin 13 and evaluated by light microscopy (Dialux 20 EB,E, Leitz GmbH, Wetzlar, F.R.G.) at x 1,000 magnification. Evaluation was performed with a specially constructed eyepiece micrometer in the ocular (Leitz). At least 1,000 intersection points at 10-/um intervals, evenly distributed over the total surface, were evaluated for each section.
Total adhesion to the matrix was defined as the percentage of the surface covered by platelets. Platelet adhesion was subdivided into contact platelets, spread platelets, and spread platelets with aggregate formation on top. 38 The last category, aggregate formation, was further divided into aggregates at least 2 fim and less than 5 jim high, those between 5 and 10 /im high, and, if present, those higher than 10 /im. As a measure of platelet-platelet interaction, the percentage of spread platelets covered with aggregated platelets was calculated; this was again divided into aggregates less than 5 fim high and those more than 5 ^m high.
Fibrinopeptide A Assays
A radioimmunoassay kit (Mallinckrodt, St. Louis, Mo.) was used for fibrinopeptide A (FPA) measurements. Before and after perfusion, 900 -fil samples from the perfusate were collected and added to 100 /il of the anticoagulant mixture provided by the manufacturers. FPA generation was calculated from the difference in FPA level just before and at the end of the perfusion. FPA generation in plasma varied in the different experiments between 50 and 150 ng/ml. To compare the results from different experiments performed on different days, FPA generation was given as the percentage of the average generation in perfusions with control blood on the same day.
Platelet Sensitivity Toward Thrombin
Venous blood of patients and healthy human volunteers, freshly drawn into citrate (1:10 volume of 130 mM trisodium citrate) was centrifuged (200g, 10 minutes at room temperature), and the PRP was collected. Platelets were then transferred into Tyrode's solution (140 mM NaCl, 2.7 mM KC1, 0.42 mM NaH 2 HPO 4 , 12 mM NaHCO 3 , pH 7.25, osmolality 300 mosm/kg) with 5 mM glucose and 3.5 mg/ml human serum albumin (Behringwerke AG, Marburg, F.R.G.) by gel filtration at room temperature on Sepharose 2B (Pharmacia, Uppsala, Sweden; column size, 5x15 cm) as described by Walsh. 39 Platelet counts were standardized at 200,000 platelets/^1 by dilution in the gel-filtration buffer. One-milliliter samples of the gel-filtered platelet suspensions, prewarmed at 37°C for 3 minutes, were stirred (900 rpm) in the aggregometer. After 1 minute, the platelets were stimulated with different concentrations (0.025-0.1 unit/ml) of a-thrombin (Sigma); stock solutions were prepared at 1,000 World Health Organization units/ml and dialyzed for 24 hours against 300 volumes of Tyrode's solution. The aggregation response was followed by measuring the disappearance of single platelets with a modified version of the method of Frojmovic et al. 40 Fifty-microliter samples of the platelet suspension were taken at 10, 20, 30,40, 50,60,90, and 120 seconds after addition of thrombin and added to 450 /A 0.5% glutardialdehyde (Fluka, Buchs, Switzerland) in PBS (1:10, vol/vol, 0.1 M NaH 2 PO 4 buffer, pH 7.4 in 0.15 M NaCl). Immediately afterward, they were analyzed in a Model 810 Platelet Analyzer (Baker Instruments) with apertures set between 3.2 and 16 ^m 3 as described by Verhoeven et al. 41 The disappearance of single platelets as a function of aggregation time was computer fitted to an exponential function. The initial rate of platelet disappearance (in percent per minute) was highly dependent on the thrombin concentration and was used as a parameter for platelet sensitivity toward that thrombin concentration as the stimulus.
Results
Laboratory Tests
The gender, age, dialysis period in months, cause of renal failure, hematocrit, platelet number, bleeding time, and clinical bleeding symptoms of the participating patients are given in Table 1 . All patients had uremic anemia. Platelet counts were normal except those for patient 5. The different methods for the measurement of bleeding time showed contradictory results. With the Simplate device, only two (patients 6 and 10) of 10 patients had normal bleeding times shorter than 8 minutes. Clinical symptoms of a bleeding tendency were present in six patients. Patients with a normal Simplate bleeding time had no symptoms. The patients with the longest bleeding times all had signs and symptoms of a bleeding disorder. With the method described by Ivy et al, only one patient (No. 1) had a prolonged bleeding time.
Routine hematologic parameters are given in Table 2. In general, overall coagulation tests, APTT, and prothrombin time were normal, as were the factors of the extrinsic pathway. The antithrombin III levels of all patients fell within the normal range (not shown). VWF: Ag parameters and factor VIII, which circulates in complex with vWF, were increased in the majority of patients. Routine aggregation assays (Table 2) with arachidonic acid and with collagen only showed one unexplained low response to collagen. Normal second-wave responses were present with ADP. Thromboxane production induced by exogenous arachidonic acid was slightly below normal levels in patients 9 and 10. Platelets of patient 5, who used nonsteroidal anti-inflammatory drugs, showed a defective thromboxane production after 10 minutes of arachidonic acid and after 5 minutes of collagen stimulation. The a-granule product in plasma, /3-thromboglobulin, a marker for platelet activation, was found to be increased in all but one patient tested. The plasma levels of PF4 (not shown), as a marker for in vitro platelet activation, were within the normal range (<10.4 ng/ml). The content of the dense granules of patient platelets, as measured by total ATP, ADP, and serotonin, was normal.
Perfusion Studies With Standardized Whole Blood
Patient and control perfusates, both normalized to equal hematocrit and platelet count, were circulated for 5 minutes at a shear of 1,300 sec' 1 over a matrix of PMA-stimulated endothelial cells. Tissue factor in these matrixes induces the formation of surfacebound thrombin. With this thrombosis model, we were able to study platelet adhesion and thrombindependent aggregate formation at the same surface. 22 One patient, having used ibuprofen the evening before the tests, showed decreased thromboxane production but was admitted, while the results obtained in whole-blood perfusions did not differ from those of the rest of the group.
In three separate experiments, three or four patients were compared over time with two controls, ( Table 3) . To compare the patients with the controls, we expressed adhesion values of patients as percentages of the average adhesion of the two controls obtained in that experiment. Adhesion was significantly decreased in the patient group (p<0.01). Table 4 shows the aggregate formation in normalized blood perfusions together with the FPA generation. Aggregates were subdivided in aggregates smaller than 5 fjm high and aggregates between 5 and 10 fim high and are given as percent of the total surface covered with spread platelets. The percentages of small aggregates (p<0.01) and aggregates higher than 5 /xm (p<0.02) were significantly decreased in the patient group. If smaller and larger aggregation values of controls are added and taken as the 100% value, then patient aggregate formation is 76.9±13.9%. FPA generation was, in general, lower in patient perfusates, but the difference was not significant. No relation was found between FPA generation and aggregate formation in the patient group (not shown).
Perfusion Studies With Reconstituted Perfusates
Perfusates were reconstituted from washed platelets, PPP, and washed control RBCs. Control platelets were suspended in patient or control plasma to test the influence of patient plasma on the function of normal platelets. Patient platelets or control platelets were suspended in control plasma to test whether the adhesion and aggregation defects as seen in the normalized whole-blood perfusions were caused by an irreversible platelet function disturbance. In each of three separate experiments, we chose to resuspend the platelets from three patients in the plasma of one control and to resuspend platelets of this one control in the three different patient plasmas. In this way, the total number of controls was limited in favor of limiting the amount of variables within the experiments.
Resuspending patient platelets in normal plasma gave decreased adhesion in all cases (Table 5) when compared with control platelets in control plasma. Plasma from seven of nine patients caused a decrease in adhesion of control platelets. When the adhesions both in patient plasma or with patient platelets were normalized to the adhesion obtained with control platelets in control plasma, similarly significant decreases of 22% and 27%, respectively, were observed Aggregate formation and FPA generation in the reconstituted perfusions are given in platelets; plasma 0-thromboglobulin (/3TG) in ng/ml. ND, not determined.
5 used nonsteroidal anti-inflammatory drugs. tValues above normal range; Rvalues below normal range. Perfusions were performed with standardized blood. Patients 1, 2, and 3 were perfused at the same time as controls 1 and 2; patients 4, 5, 6, and 7 at the same time as controls 3 and 4; patients 8, 9, and 10 at the same time as controls 5 and 6. Adhesion is given in percentage surface coverage (SC) (mean±SEM, TI=4); adhesion is also normalized to the mean adhesion value of the two controls perfused in the same experiment (C=100%), mean±SEM. Patient No. 5 used ibuprofen more than 18 hours before the experiment. The effects of ibuprofen on aggregation are reversible; moreover, the serum t 1/2 of 2 hours makes the drug's influence unlikely. FPA generation in perfusates with patient plasma was increased (146% of control generation), but this difference was not significant. FPA generation in perfusates with control plasma was not influenced by the presence of patient platelets (106%).
Platelet Sensitivity Toward Thrombin
The platelets of patients were tested for their sensitivity toward different thrombin concentrations (Figure 1 ). Gel-filtered platelets were prepared to avoid the influence of plasma proteins on the assay. The aggregatory response was followed in time by screening the suspension for remaining nonaggregated single platelets. 41 Figure 1 , upper panel, shows an example of a typical response with various thrombin concentrations. The disappearance rate of the single Perfusions as described in legend to Table 3 . Platelet-platelet interaction (mean±SEM, /i=4) is given as percentage aggregates (Aggr) <5 fitn and between 5 and 10 /im of total surface (TS) covered with spread platelets. Percent fibrinopeptide A (FPA) generation (gen) is normalized to mean FPA generation found with two perfused controls, mean±SEM.
'p<0.01, +p<0.02 compared with controls (Student's I test). Perfusions were performed with reconstituted blood. Plasma and platelets (Pit) of patients 1, 2, and 3 were reconstituted with platelets, plasma, and red blood cells of control 1; of patients 5, 6, and 7 with control 2; of patients 8, 9, and 10 with control 3. Adhesion is given in percentage surface coverage (SC) (mean±SEM, n=4); adhesion is also given as percentage of adhesion of its control (C=100%), mean±SEM.
•p<0.01 compared with 100% (Student's / test).
platelets was computed by exponential curve fitting. In Figure 1 , lower panel, the disappearance rate for eight patients was compared with that of five controls. Increasing thrombin concentrations increased the disappearance rate. No differences were observed between patient and control platelets. Therefore, intrinsic platelet defects in response to stimulation with exogenous thrombin could not be detected.
Discussion Uremia is associated with a bleeding disorder. Clinical bleeding symptoms in these patients correlate best with prolonged skin bleeding times.
2 Accordingly, also in our group of patients, clinical bleeding symptoms were associated with abnormal Simplate bleeding times. The normal bleeding times we obtained with the often-used method as described by Ivy et al 24 did not rule out a bleeding tendency (Table 1) and is, therefore, not preferable. Defective platelet-vessel wall interaction is the most likely cause for the bleeding disorder. Adhesion and aggregation of blood platelets to exposed subendothelium are the first steps in normal nemostasis. 11 Collagen, exposed when deeper vessel-wall injury occurs, and thrombin generated by tissue factor-initiated coagulation are the main in vivo stimuli of platelet aggregation. The platelet aggregates reinforced and interlinked by fibrin form the eventual hemostatic plug.
The transport of platelets toward the vessel wall and, therefore, both platelet adhesion and aggregation are strongly dependent on the shear rate of the blood.
13
- 16 In flow, hematocrit 12 -15 also determines the availability of platelets for interaction with the vessel wall. Platelet count, 12 platelet function, vWF, and fibronectin in plasma 42 " 45 and adhesive mole- No. Therefore, in vitro studies about the pathophysiological factors influencing uremic hemostasis should be performed under well-defined flow conditions. In these perfusion systems, the low hematocrit in uremic patients was shown to be a major factor, which causes defective hemostasis. The low amount of RBCs in uremic anemia causes inadequate transport of platelets toward and therefore lower adhesion and aggregation on the vessel wall. Additionally, we 21 and others 47 have shown that uremic blood perfused at normal hematocrits contains an unknown toxin that inhibits platelet adhesion to artery segments. Whether such toxins in uremic plasma or intrinsic defects in uremic platelets also inhibit thrombin formation, thrombin-stimulated aggregation, and fibrin generation as subsequent processes important for hemostatic plug formation are not known and so far, have not been studied.
In this article, we investigated these matters by perfusing uremic whole blood over matrixes of stimulated endothelial cells. Stimulation of cultured endothelial cells results in synthesis and deposition of tissue factor in their matrix. When this matrix is exposed to perfusates anticoagulated with LMWH, local thrombin is generated via complex formation between factor Vila and tissue factor. In the system, thrombin is formed through directly activated factor X and is not dependent on factor IX. 22 In contrast to normal unfractionated heparin, LMWH allows the formation of local and matrix-associated thrombin and its action of platelet aggregate formation. At the concentration used, however, the LMWH does prevent thrombin activity in the circulation. In citrated blood, local formation and action of thrombin cannot be studied. If LMWH perfusates or citrated perfusates are circulated over tissue factor-poor matrix of unstimulated endothelial cells, comparable adhesion but a much lower aggregate formation are seen. The remaining aggregate formation, however, is equal in both perfusates. 21 Therefore, LMWH as an anticoagulant in the perfusates does not influence thrombin-independent function when compared with the commonly used anticoagulation with citrate. The pronounced aggregate deposition on the tissue factor-rich matrix and generation of FPA in the perfusate can be attributed to the action of thrombin on platelet aggregation and fibrin formation. The generation of FPA, a stable degradation product from fibrinogen, is taken as an indirect marker of thrombin activity. With this new thrombosis model, 22 we studied platelet adhesion simultaneously with thrombindependent aggregate formation in uremic blood. The blood of 10 uremic patients (Table 1) on chronic dialysis treatment with generally normal coagulation tests, normal aggregometer tests, normal thromboxane metabolism, and a normal content of platelet granules (Table 2) was collected just before a hemodialysis session and used for perfusions. We only studied patients just before one of their hemodialysis treatments because the hemodialysis membrane itself and the unfractionated heparin in use during the dialysis procedures are able to cause decreased platelet count 4849 and disturbed function.
-50
To study the processes that were not dependent on the hemodynamic influence of the low hematocrit in these patients, we first standardized both patient and control whole blood to perfusates with equal hematocrit and platelet number. 21 A clear adhesion defect was seen in the patient group (Table 3) . Normal platelets resuspended in uremic plasma also showed an adhesion defect ( Table 5 ). The adhesion defect was equal to that observed in the perfusions with standardized uremic whole blood (Table 3 ). These results indicate that platelet adhesion is inhibited by a plasma factor. A similar plasma-induced adhesion defect was reported at artery segments. 21 However, the adhesion defect to artery segments can be compensated for by increased levels of vWF, 21 which are often present in uremic plasma. 51 - 32 Adhesion to the ECM as described here is much less dependent on vWF in the perfusate. 36 The high levels of vWF in uremic plasma (Table 2) are, in this case, not able to compensate for the deleterious influence of the same plasma on adhesion to the ECM.
Additionally, a clear aggregation defect was seen in uremic patients with standardized whole-blood perfusions (Table 4) . Although less FPA was generated in the uremic whole-blood perfusates, this difference was not significant. In contrast, normal coagulation tests in uremic patients gave us no reason to suspect abnormal thrombin formation in uremic blood; a decreased thrombin generation for which FPA generation is a marker, however, might offer an explanation for the decrease in aggregate formation. LMWH in uremic plasma was somewhat less effective in prolonging the kaolin-cephalin clotting time as was LMWH in control plasma. This phenomenon would theoretically lead to increased thrombin, aggregate formation, and FPA generation in uremic blood. In fact, reconstituted perfusates with patient plasma showed a tendency for increased FPA generation. As with the uremic wholeblood perfusions, diminished platelet-platelet interaction 21 was still observed when normal platelets were resuspended in this uremic plasma (Table 6 ). Thus, a plasma factor that inhibits thrombin-dependent platelet aggregation without influencing the thrombin formation responsible for fibrin formation is the best explanation for the combined results.
An intrinsic platelet defect might also be present in uremia. Indeed, washed uremic platelets resuspended in control plasma showed decreased adhesion (Table 5 , 72.9%) and decreased thrombin-dependent aggregation (Table 6 , 72.3% of control aggregation). However, from the perfusion experiments with reconstituted perfusates, we are not able to discern between platelet defects caused by uremic toxin(s) that were not reversible by wash procedures and intrinsic platelet defects. Uremic plasma was able to induce defects in the adhesion of control platelets (Table 5 , 77.8%) compared to those seen when uremic platelets were suspended in their own plasma (Table 3 , 72.3%); compared with control aggregate formation, control platelets in uremic plasma showed even larger defects than were observed for uremic platelets in uremic whole blood (Tables 4 and 6 , 55.0% versus 76.9%). These results indicate that uremic plasma alone is able to cause the full extent of adhesion and aggregation defects present in uremic whole blood. Moreover, the aggregometer assay showed normal sensitivity of gelfiltered uremic platelets for threshold thrombin concentrations. Thus, in the aggregometer, no intrinsic defects of washed uremic platelets concerning thrombin-dependent aggregation could be observed. In contrast, when washed uremic platelets were suspended in control plasma, they still showed, in perfusions, the same defects as they did in uremic whole blood. The defects induced by uremic plasma seem to be associated with platelets and are not easily reversed either by the washing procedures or by resuspension of patient platelets in control plasma. The absence of defects for washed platelets in the aggregometer study may be explained by the higher shear forces in the perfusion system that may prevent aggregate formation that is still allowed in the aggregometer. Another explanation, that uremic platelets are less responsive to locally formed thrombin at the matrix than they are to exogenously added stimuli, seems less likely. Platelets have also been described to contribute to the formation of thrombin by supplying extra phospholipid surface on which coagulation factors can interact. 53 - 54 Inhibited formation of endogenous thrombin at the surface of platelets 55 -58 might result in defective aggregation. In our system, the normal FPA generation in reconstituted perfusates with uremic plasma or platelets seems incompatible with this mechanism.
When expressed as a percent of control values, no significant correlation was found between patients' adhesion and aggregation values (coefficient for standardized blood perfusions, -0.178; coefficient for control platelets in patient plasma, 0.209; coefficient for patient platelets in control plasma, -0.239). This indicates that adhesion and aggregation in patients are separate and distinct properties. Uremic conditions are able to inhibit both properties independently and to a various extent in each uremic patient.
Aggregometry studies with uremic platelets have been performed for many years, 5960 and many authors have reported an abnormal function of uremic platelets. 60 - 67 However, these aggregometer tests with PRP have shown inconsistent and contradicting results. The large variety in aggregometry methods and the absence of standardization make the comparison between various findings extremely difficult. These problems might be finally solved; the most important limitations will remain. They originate from the fact that in contrast to perfusion studies, aggregometer systems cannot study platelet function under well-defined flow conditions in the presence of RBCs and an injured vessel wall. In our patient group, aggregometer studies with PRP did not reveal consistent abnormalities; the same patient group, in contrast, showed significant aggregation defects in our thrombosis model. Therefore, adhesion and aggregation defects observed in systems closely resembling physiological conditions are more likely to represent the true pathophysiology of the uremic bleeding tendency.
Thus, uremic plasma factors not only inhibit platelet adhesion but also they most likely inhibit the response of platelets to endogenously formed thrombin, causing decreased aggregate formation. In accordance with these findings, collagen-induced aggregate formation is also inhibited by uremic plasma (J.J. Zwaginga et al, unpublished observations). Besides thrombin, collagen is the second strongest stimulus of platelet aggregation and is exposed to flowing blood when deeper vessel-wall injuries are present. Which factors in the plasma of regularly dialyzed patients are responsible for these findings remain to be investigated. "Middle molecules" with a molecular weight between 500 and 2,000 d, 68 such as aromatic and indolic organic acids like hippuric acid and phenolic acid, 69 are difficult to remove from and therefore tend to accumulate in hemodialysis patients. 70 The list of urerriic toxins that possibly inhibit platelet function should at least include these metabolites. 65 
